ARS Pharmaceuticals Q1 Loss of $0.61, Revenue Beats at $22.68M with $17.5M Neffy Sales
SPRY•ARS Pharmaceuticals lost $0.61 per share in Q1 versus a $0.53 estimate and posted $22.68 million in revenue, beating forecasts by $0.48 million with neffy sales of $17.5M. Its current ratio is 4.94 as it grows to 148 reps, secures a CVS Caremark deal, plans a Q4 2026 clinical readout.
1. Q1 Financial Results
ARS Pharmaceuticals reported a loss of $0.61 per share for Q1, deeper than the $0.53 estimated and prior-year’s $0.35 loss, while revenue climbed to $22.68 million, surpassing forecasts by $0.48 million and driven by $17.5 million in neffy U.S. sales.
2. Financial Position
The company’s current ratio of 4.94 underscores solid liquidity and ability to meet short-term obligations, though a negative P/E of -3.79 reflects ongoing unprofitability. ARS has expanded its commercial team to 148 representatives to support market uptake.
3. Growth Strategy
ARS Pharmaceuticals is finalizing a partnership with CVS Caremark expected in early June and is preparing for a pivotal clinical study readout due in Q4 2026 to advance its allergy treatment pipeline.
